Skip to content

A Study to Assess the Effect of Sarpagandhadi Mucoadhesive Patch in Stage 1 Hypertension Patients.

Design, Optimization, In Vivo and Clinical Assessment of Sarpagandhadi Mucoadhesive Patch in the Management of Essential Hypertension Stage 1. - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/111331
Enrollment
30
Registered
2026-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

Parul Institute of Ayurved
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either gender between the age of 20 and 70 years Known cases of Stage 1 Essential Hypertension who are not receiving any antihypertensive drug. Patients with Stage 1 Essential Hypertension having systolic blood pressure between 140 to 159 millimetre of mercury and diastolic blood pressure between 90 to 99 millimetre of mercury will be included

Exclusion criteria

Exclusion criteria: Patients with secondary hypertension having systolic blood pressure between 160 to 179 millimetre of mercury and diastolic blood pressure between 100 to 109 millimetre of mercury. Patients suffering from acute hemorrhagic conditions, acute septic shock, and ischemic heart disease. Patients with a known history of hypertension for more than 12 years and diabetes mellitus. Patients with hypertensive emergency, that is blood pressure more than 180 over 120 millimetre of mercury, and pregnancy induced hypertension. Pregnant and lactating women. Patients with any chronic disease or those who have undergone major surgery and other systemic illnesses will be excluded.

Design outcomes

Primary

MeasureTime frame
Reduction in systolic and diastolic blood pressure (SBP & DBP) from baseline after treatment with Sarpagandhadi rapid patch. Lipid Profile and ECG on screening Timepoint: Assessment at baseline and on Day 15 of treatment

Secondary

MeasureTime frame
To conduct a safety evaluation of the sublingual delivery system.Timepoint: For 15 Days.

Countries

India

Contacts

Public ContactDr Dipeeka Surwase

Parul Institute of Ayurved

dipeeka.surwase21816@paruluniversityac.in9860750957

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026